Oncology Business Management | Specialty

Choosing Among TKIs in Advanced RCC

June 29th 2016

Determining Initial Therapeutic Approach in Advanced RCC

June 29th 2016

Goals of Therapy in Advanced RCC

June 29th 2016

When to Start Systemic Treatment in Newly Diagnosed RCC

June 29th 2016

FDA Grants Lutathera Priority Review for Neuroendocrine Tumors

June 27th 2016

The FDA has granted a priority review designation to Lutathera (177Lutetium DOTA-octreotate) as a treatment for patients with gastroenteropancreatic neuroendocrine tumors.

HHS Rejects Bid to Broaden Access to Enzalutamide

June 23rd 2016

The Department of Health and Human Services has turned down a request to override the patent for prostate cancer drug enzalutamide (Xtandi) so that it can be sold to a broader base of patients at a reduced price.

Finding Time for Stress Relief Increasingly Difficult for Oncologists

June 15th 2016

Many doctors in oncology are pushing themselves to the extreme, and longer workdays have become a fact of life.

Experts: No Savings From Smaller Cancer Drug Packages

June 14th 2016

Two researchers have challenged the notion that money can be saved by packaging medications in sizes that conform more closely to patient weight and dosing needs.

Feeling Chafed by Cigna's Genetics Policy

June 13th 2016

Cigna's new policy is an extension of a previous Cigna requirement for the use of certified genetic counselors for breast, ovarian, and colorectal cancer genetic tests.

Patient Longevity Will Be Key Driver in Hematology Market Growth

June 12th 2016

Incoming generic and biosimilar substitutes for dominant, brandname hematology drugs may lead to less costly treatment, but a lot will depend on the quality and supply of these new products,

A Value Proposal That Will Raise Costs

June 11th 2016

It seems to be that there is a "minor" disagreement between ASCO and CMS about the approach to address value in cancer care delivery.

Florida Practices Band Together for Strength

June 9th 2016

Florida Cancer Specialists & Research Institute has honed its merger strategy into a finely tuned regimen that goes from due diligence to planning to implementation and follow-up, all in a period as short as 120 days.

Reduce Exposure to Financial Risk With a Financial Counseling Program

June 8th 2016

A well-tailored financial counseling program can help a practice minimize exposure to financial risks due to increasing patient responsibility.

Global Oncology Drug Spending Reaches $107 Billion

June 2nd 2016

The global cost of cancer therapies shot up to $107 billion in 2015, an 11.5% rise from the $100 billion 2014 total for oncology therapeutics and supportive care drugs.

Direct Contracting Is the Key to Bypassing the Payer

June 1st 2016

Under direct contracting, a provider signs an agreement with a business or membership organization outlining the care to be provided and the payment scheme, cutting out the insurer completely.

CMS Puts On Its Poker Face

June 1st 2016

The saying on Wall Street is "sell in May and go away," but there's no detaching from the cliffhanger that CMS has left in the air.

New Blockbusters Will Offset Generic Price Erosion in Hematology

May 31st 2016

Hematological practices can expect a slate of new generics to replace long-established brand drugs going off patent, as well as new blockbuster blood therapies that will significantly improve the treatment of some malignancies.

ABIM Offers a Less Burdensome Path to Maintenance of Certification

May 18th 2016

The American Board of Internal Medicine has promised to roll out a series of short assessments that could potentially be taken in the privacy of one’s home or office and via an open book exam.

Changing Drug Packaging Won't Eliminate the Waste

May 17th 2016

Two researchers have challenged the notion that money can be saved by packaging medications in sizes that conform more closely to patient weight and dosing needs.

FDA Approves Lenvatinib/Everolimus for Advanced RCC

May 13th 2016

The FDA has approved the combination of lenvatinib and everolimus as a treatment for patients with advanced renal cell carcinoma (RCC) following prior anti–angiogeneic therapy